BAJAJ BROKING
Cipla Limited has reported consolidated Q2 results for FY24-25, showcasing a steady rise in financial performance. The company recorded a revenue of ₹7,051 Cr, an 8.6% YoY increase, and a PAT of ₹1,303 Cr, marking a 16.9% growth. This growth is attributed to strong sales across segments, particularly in India and North America.
Cipla’s quarterly performance has been buoyed by growth in domestic and North American markets, with substantial improvements in the chronic segment
Other Income:Expenses:
Metric | Q2 FY25 | Q2 FY24 | YoY % Change |
Revenue from Operations | ₹7,051 Cr | ₹6,678 Cr | 8.60% |
EBITDA | ₹1,886 Cr | ₹1,689 Cr | 11.60% |
PAT | ₹1,303 Cr | ₹1,155 Cr | 16.90% |
EBITDA Margin | 26.70% | 26.00% | +70 bps |
PAT Margin | 18.50% | 17.20% | +130 bps |
Employee Benefits Expense | ₹1,208 Cr | ₹1,091 Cr | 9% |
Depreciation & Amortization | ₹272 Cr | ₹290 Cr | -6% |
One India:North America:Africa and Emerging Markets:
Sector Expectations for Cipla 2Q Results FY24-25
Cipla's results align with sector expectations, especially in chronic therapies like respiratory and cardiac, where growth continues despite industry challenges. The management's strategic focus on high-growth markets has been instrumental in surpassing sector benchmarks.
Management Commentary
Cipla’s management expressed satisfaction with the quarter’s performance, attributing growth to strategic launches and robust demand in core therapeutic areas. The leadership emphasized continued investment in R&D and expansion across high-growth segments.
Check out Cipla's past performances in previous quarters and financial years.
Cipla’s Q2 FY24-25 results underscore its growth trajectory in both domestic and international markets. With a strong pipeline, particularly in the North American generic segment, Cipla remains committed to sustainable growth. The company's strategic focus on key therapies and segments continues to drive value for stakeholders.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading